匯頂科技(603160.SH):註銷71.48萬份股票期權
格隆匯3月5日丨匯頂科技(603160.SH)公佈,公司於2023年3月4日召開第四屆董事會第十八次會議及第四屆監事會第十七次會議,審議通過了《關於註銷部分股票期權的議案》,同意將2018年股票期權激勵計劃、2019年股票期權與限制性股票激勵計劃、2020年股票期權與限制性股票激勵計劃、2021年第一期股票期權激勵計劃、2021年第三期股票期權激勵計劃、2022年第一期股票期權激勵計劃中部分激勵對象已獲授但尚未行權的全部股票期權合計714,819份進行註銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.